management team

Jean Louis Escary – founding CEO & Chairman, PHD

CEO and founder of GenOdyssee in October, 1999
Jean-Louis Escary is an internationally renowned pioneer in cytokine genetics and human genome variation technologies
Ph.D. in 1994 in cellular and molecular biology from Université Pierre et Marie Curie in Paris, France Researcher at Institut Pasteur in Paris, France, from 1988 to 1996 then post-doctoral fellowship at Department of Medicine, UCLA from 1996 to 1998, researcher at the Wellcome Trust Centre for Human Genetics (Oxford, UK) in 1998, Head of the genome variability program at the Centre National de Génotypage (French National Genotyping Center or CNG) from 1998 to 1999
Author or co-author of 67 publications, patents and patent applications
HBS’ Essential Business Strategies Course (Robert Kennedy College, Zurich, Switzerland, 2003)

Bertrand Lellouche, Chief Finance Officer, MBA

20 years experience in finance in privately owned and publicly trade companies; Technomed, Coflexip, Vivendi Environnement, GenOdyssee, BMD, CFO at SpineVision)

As head of the genome variability program (1998-99) at the French national genotyping center, he also completed with his team the first high density SNP map of the human chromosome 14 (Genomics 70, 153-164, 2000), and invented with Pr Beckmann (co director of CNG) an innovative multiplexing method for doing high throughput SNP discovery using denaturing-high performance liquid chromatography (D-HPLC) that enabled the discovery of novel pathogenic mutations not detected by sequencing (Human Mutation, 16, 518-526 (2000).

Dr Escary founded GenOdyssee SA in October 1999 with the support from ANVAR, the French Agency for Innovation, and Génopole 1er Jour, the Evry Génopôle incubator. He is the inventor of the innovative drug discovery approach and product pipeline of GenOdyssee. As CEO of the company, he raised to date €19.3 (USD25) million from French biotech venture funds. Since its inception, the company received €4.0 (USD5.2) million from French government tax credits and generated €2.15 (USD2.8) million in revenue.

Dr Escary is a member of the New York Academy of Sciences (NYAS), the American Chemical Society (ACS), and was an alumni of the Young Leaders Program (2005) of the French-American Foundation (NY, USA).

Rewards
2000: "Golden 91" award from the French entrepreneurial association "MEDEF";
2003: "the Merit for the Development of Research (post-genomics)" from the "Institut International de Promotion et de Prestige" (Geneva, Switzerland)

Publications - Inventorship
Dr Escary has published in leading peer-reviewed scientific journals including Nature and Neuron and is the author to date of 67 publications, patents, and patent applications.

Contact
Dr Jean-Louis Escary Chairman & CEO
Mobile phone: +33 (0) 6 16 41 68 57
Fax: +33 (0) 1 60 87 89 99
E-mail: escary@genodyssee.com
URL : www.genodyssee.com

Up page

Experienced and renowned scientific and clinical experts working from time to time with the company

Professor Fabien Zoulim: top European clinical expert in HCV, INSERM (Lyon)

Director of the Viral Hepatitis Laboratory (INSERM unit 871), Lyon (France) who has already conducted and participated to numerous multi centric international clinical studies and trials for HCV and HBV drug candidates at the Liver Department, Hôtel Dieu Hospital (Lyon, France). His clinical expertise and experience are well recognized internationally and include participation to Hepatitis B and C trials involving pegylated IFN as well as small antiviral molecules trials for the major biotech and pharma companies.

Professor Hervé Fridman: leading international cancer and immunotherapy expert, INSERM (Paris)

Head Department of Immunology - Hopital Europeen Georges Pompidou and Director of the Centre de Recherche des Cordeliers (Paris, France). His scientific and clinical expertise in immunotherapy of cancer is well recognized internationally. In particular, Pr Fridman has accumulated a very extensive scientific and clinical expertise in solid tumors, and has conducted or participated to numerous cancer trials including with IFN drugs.

Professor Michael Tovey: Pioneer in IFN Research

Laboratory of Viral Oncology, UPR 9045 CNRS, Villejuif (France) Professor Tovey is internationally recognized as one of the pioneers in IFN research

Professor Jacques Beckmann: International leading expert in Human and Medical Genetics

Former Director of Research at the Fondation Jean Dausset - CEPH, Paris and Scientific Director of the CEPH database
Professor at the Weizmann Inst. of Sciences (Rehovot, Israel), CSO of Genethon (Evry, France) Co-founder and Associate Director General of the French National Genotyping Center (Evry, France), Pr Beckmann has an international reputation in the field of human genetics and medical genetics Pr Beckmann advises the Company from time to time on these subjects and is one of the first supporters of the drug discovery approach invented by GenOdyssee

Director, High Throughput Discovery Platform: Emmanuel Bottius

got his Ph.D. in molecular biology at the University of Paris 7. From 1987 to 1997, he developed new molecular tools for the study of plasmodium falciparum, at Pitié-Salpétrière Hospital in Paris, in the department of Professor Gentillini and in Pasteur Institute in department of biomedical parasitology of Dr Druilhe . After several months at the New York Medical Center, he joined the Pasteur Institute under the supervision of Dr Artur Scherf to study the genome variability of plasmodium falciparum and

the survival process of the parasite in infected patients.
For instance, he developed the first strain-specific PCR assays for a robust detection of the different forms of the parasite.
From 1998 to May 2000, he joined the Genome Variability program of CNG (French National Genotyping Center) under the supervision of Dr J.L. Escary where he was head of the SNP high throughput discovery platform.

Vice-President Strategic Planning :Jean-Marc Giry

brings over 20 years of marketing and business development experience to GenOdyssee. He joins the company from X-PM Transition Partners, an Executive Interim and Transition Management Services company. Prior to this, Jean-Marc held the positions of Vice President, Strategic Marketing at Gemplus, the leading smart cards manufacturer, and of Director of Marketing for the French subsidiary of Oracle, the leading database and enterprise software vendor. In those positions, he developed a strong expertise in fields such as international management,

business modelling and strategic planning, market positioning, and global communications of publicly traded companies. Jean-Marc received his MBA in enterprise management from H.E.C., the Jouy-en-Josas (France)-based business school in 1981, as well as a Master's Degree in Computer Sciences from Dauphine University (Paris, France) in 1982.

Vice-President Finance & Administration : Bertrand Lellouche

got his Master of Science in International Management at the MBA Institute in Paris. He has 15 years experience in international financial management in publicly traded companies : Technomed (medical), Coflexip (oil services) and Vivendi (environment), including 3 years based in Germany and the U.K. Before joining GenOdysse,

he was recruited by Vivendi to organize the finance and administration of its international water network activities. Prior to Vivendi, he held several senior financial positions including the financial control and management of Coflexip International. Bertrand Lellouche brings an extensive expertise in project management, financial control, human resources, administration and communication in an international environment.

Vice-President Preclinical and Clinical Development:Jean Maral

holds an MD from Internat des Hopitaux de Paris and a PhD in biochemistry. Dr Maral joins GenOdyssee from CHIRON Biopharmaceuticals Europe, where he had served as Director of Clinical and Scientific Affairs since 1995. While at Chiron, Dr Maral was responsible for the successful multinational organisation of clinical and preclinical development for several oncology, hematology and infectious disease products.

Before joining CHIRON Biopharmaceuticals, Dr Maral served successively as Director of Clinical Research with PIERRE FABRE Laboratories, then Medical Director with Amgen France. Dr Maral will be in charge of developing the therapeutic protein variants discovered by GenOdyssee.

Director, Protein Science:Thierry Menguy, Ph.D.

got his Ph.D. in Enzymology, Structure and Engineering of proteins at the University of Paris Sud (Paris XI, Orsay). From September 1995 to August 2000, he worked at CEA (French Atomic Energy Commission) in the protein and membrane biophysics group headed by Prof Marc le Maire (CEN Saclay, France) where he acquired a strong experience in protein expression and purification, and the identification and characterization of soluble and membrane protein active sites.

Thierry Menguy joined GenOdyssee in August 2000 where he brings an outstanding expertise in proteins and where he is in charge of high throughput production and purification and protein-protein interaction analysis of protein candidates for internal screening and pre-clinical studies.

Senior Project Manager Pre clinical Development & Production : Yves Joulin, Pharm D, Ph.D.

pharmacist, got its Ph.D. in neurosciences at the university of Paris XII. He has over 10 years of experience of product development in the pharmaceutical industry (neurological, inflammatory and cardiovascular products). Before joining Genodyssee, he was Head of Pharmacological Studies at Servier (1991-1994) in the area of cardiovascular, and then he joined Bioprojet, a company developing products in the areas of neurology, cardiology, and inflammation, as Director of Pre Clinical Development for 6 years. More recently, Yves Joulin was Senior Pre Clinical Project Manager, at Ferring Pharmaceuticals, a company developing cardiovascular and analgesic drugs.

Yves Joulin joined GenOdyssee on January 2002 as Senior Project Manager. He is in charge of the pre clinical development and production of GenOdyssee's therapeutic protein variants.

Pr Hervé Fridman:

Cancer and Immunotherapy (Pharmacology & Clinical) U255 INSERM, Centre de Recherches Biomédicales des Cordeliers, 15 rue de l'Ecole de Médecine; Hôpital Georges Pompidou, Paris (France)

Pr Michael Tovey:

Infectious Diseases & Cancer (Pharmacology) Laboratory of Viral Oncology, UPR 9045 CNRS, Villejuif (France)

Pr Fabien Zoulim :

Hepatitis C (Pharmacology & Clinical) Laboratoire des Virus des Hépatites et Pathologies Associées, Unité 271 INSERM, Lyon (France)

IFN alpha

Infectious diseases & cancer: Pr Michael Tovey Laboratory of Viral Oncology, UPR 9045 CNRS, 94800 Villejuif (France). Cancer and immunotherapy: Pr Hervé Fridman U255 INSERM, Laboratoire " Immunologie Cellulaire et Clinique ", Centre de Recherches Biomédicales des Cordeliers, 15 rue de l'Ecole de Médecine, 75006 Paris (France). Professor at Service d'immunologie, Hôpital Georges Pompidou (France).
Autoimmune diseases: Pr Pierre Miossec Hôpital Edouard Herriot, Service de Rhumatologie, Unité d'Immunologie Clinique, 5 place d'Arsonval, 69003 Lyon (France).

Hepatology: Pr Stanislas Pol Hôpital Necker Enfants Malades, Service Gastro-Entérologie, 149 rue de Sèvres, 75015 Paris (France).

EPO

Hematology: Dr Nicole Casadevall

Department of Hematology, Hôpital Hôtel Dieu, Paris (France).

Up page

In 2005, GenOdyssee evolved into a virtually-integrated company model, a low cash burn structure designed to go swiftly through all biotech economic cycles. GenOdyssee outsources its activities from discovery to formulation and clinical development. Senior management team is constituted of the founding CEO and chairman and the CFO accompanied by two international senior advisors, altogether counting for more than 80 years of senior management experience in pharmaceutical R&D in the field of protein therapeutics, finance and capital risk. A team of 4 additional project managers supervises the work implemented by the company’s services providers. The VIPCO model relies on a strong partnership with service provider subcontractors, which can perform virtually drug discovery programs as well as all the preclinical stages of drug development. The Company and its providers are linked by a mutual confidentiality agreement securing the protection of GenOdyssee’s unique technology process and discoveries.